CD8A and prostate cancer: Our laboratory has recently shown that targeting MDSCs using anti-CSF1R in combination with VTP therapy not only decreased the numbers of intratumoral MDSCs and TAMs, but also increased CD8+ T cell infiltration, decreasing tumor growth and improving overall survival in a prostate cancer model [37].